암 지지 치료제 시장 : 유형별, 용도별, 유통 채널별 - 세계 기회 분석과 산업 예측(2023-2032년)

Cancer Supportive Care Drugs Market By Type, By Application, By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2023-2032

US $ 6,090 ￦ 8,491,000

PDF (Business License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄는 5회 가능하며, 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다. 2명 이상이 이용할 경우, 추가 요금을 지불하여 라이선스 업그레이드로 최대 5명까지 이용 가능합니다.

US $ 10,500 ￦ 14,640,000

PDF (Enterprise User License) & Excel (Data Pack) & Free Update

PDF 보고서 및 Excel 데이터를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다. 보고서 업데이트 서비스가 무료로 제공됩니다.

한글목차

암 지지 치료제를 촉진하는 주요 요인에는 암의 유병률 상승 및 화학요법에 따른 빈혈, 구역, 구토 등의 항암제 사용에 수반하는 부작용이 있습니다.

예를 들어 2022년 2월 세계보건기구(WHO)는 전 세계에서 매년 약 40만 명의 어린이가 암에 걸린다고 추정했습니다. 또한 2022년 4월 미국 국립생물공학정보센터(NCBI)가 실시한 조사에 따르면 유방암 환자의 빈혈 발생률은 약 41.1%로 추정됩니다. 따라서 암 유병률 증가가 시장 성장을 주도하고 있습니다.

또한 노인은 암에 걸릴 확률이 높기 때문에 다양한 부작용을 치료하기 위한 암 보조 치료제에 대한 수요가 더욱 증가하고 있습니다. 예를 들어 2022년 10월 세계보건기구(WHO)는 60세 이상 세계 인구가 2050년까지 두 배로 증가하여 21억 명에 달할 것으로 추산했습니다. 또한 미국 국립생물공학정보센터(NCBI)에 따르면 고령자들은 암 치료의 결과로 빈혈을 경험할 것으로 예상됩니다. 또한 암 치료로 인한 부작용에 대한 환자와 의료 전문가들의 인식이 높아지면서 암 치료 보조제에 대한 선호도가 높아지고 있습니다.

또한 암 치료로 인한 부작용에 대한 환자와 의료 전문가들의 인식이 높아지면서 암 보조요법에 대한 선호도가 높아지고 있습니다. 또한 암 치료 중 환자의 삶의 질 향상에 대한 관심이 높아지면서 효과적인 솔루션에 대한 수요가 증가하고 있습니다. 암 발병률이 특히 소아 및 노인과 같은 특정 계층에서 지속적으로 증가함에 따라 지지요법에 대한 수요는 지속적으로 증가할 것으로 예상되며, 이는 종합적인 암 치료에서 지지요법이 매우 중요한 역할을 할 수 있음을 지원합니다.

암 지지 치료제 시장은 시장의 상세한 평가를 제공하기 위해 유형, 애플리케이션, 유통 채널 및 지역에 따라 세분화됩니다. 유형별로는 적혈구 조혈 자극제(ESA), 과립구 집락 자극제(G-CSF), 구토 억제제, 비스포스포네이트, 오피오이드, 비스테로이드성 항염증제(NSAIDs), 기타로 분류됩니다. 용도별로는 유방암, 폐암, 대장암, 전립선암, 간암, 위암, 기타로 분류됩니다. 유통 채널별로는 병원 약국, 드럭스토어 및 소매 약국, 온라인 프로바이더로 세분화됩니다. 지역별로는 북미(미국, 캐나다, 멕시코), 유럽(독일, 프랑스, 영국, 이탈리아, 스페인, 기타 유럽), 아시아태평양(중국, 일본, 인도, 호주, 한국, 기타 아시아태평양), 남미(브라질, 사우디아라비아, 아프리카, 기타 남미)로 나뉩니다.로 분석됩니다.

이해관계자 주요 이점

• 이 보고서는 2022-2032년 암 지지 치료제 시장 분석 시장 부문, 현재 동향, 추정 및 역학에 대한 정량적 분석을 제공하여 암 지지 치료제 시장의 유력한 시장 기회를 식별합니다.
• 시장 성장 촉진요인, 시장 성장 억제요인, 시장 기회와 관련된 정보와 함께 시장 조사를 제공합니다.
• Porter's Five Forces 분석은 이해 관계자가 이익 중심의 비즈니스 결정을 내리고 공급자와 구매자의 네트워크를 강화할 수 있도록 구매자와 공급자의 잠재력을 밝힙니다.
• 암 지지 치료제 시장 세분화를 자세히 분석하여 시장 기회를 파악할 수 있습니다.
• 각 지역의 주요 국가는 세계 시장에 대한 매출 기여도에 따라 매핑되어 있습니다.
• 시장 기업의 포지셔닝은 벤치마킹을 용이하게 하고 시장 기업의 현재 위치를 명확하게 이해할 수 있습니다.
• 이 보고서에는 지역별 및 세계 암 지지 치료제 시장 동향, 주요 기업, 시장 부문, 용도 및 시장 성장 전략에 대한 분석이 포함되어 있습니다.

이 보고서에서 가능한 보고서 커스터마이징

• 국가, 지역 및 세계 수준의 환자/역학 데이터
• 규제 가이드라인
• 고객의 관심사에 따른 추가 기업 개요
• 국가별 또는 지역별 추가 분석 - 시장 규모 및 전망
• 기업 개요 확장 리스트
• 과거 시장 데이터
• SWOT 분석

목차

제1장 서론

제2장 주요 요약

제3장 시장 개요

• 시장의 정의와 범위
• 주요 조사 결과
  • 영향요인
  • 주요 투자 기회
• Porter's Five Forces 분석
• 시장 역학
  • 촉진요인
    • 노인 인구의 증가
    • 암의 유병률 상승과 항암제 사용에 수반하는 부작용의 증가
    • 암 지지 치료제의 채택 증가
  • 억제요인
    • 암 표적치료의 진보
  • 기회
    • 암 지지 치료제 연구개발 및 파이프라인 수의 증가

제4장 암 지지 치료제 시장 : 유형별

• 개요
• 적혈구 조혈 자극인자 제제
• 과립구집락자극인자
• 항구토제
• 비스포스포네이트
• 오피오이드
• 비스테로이드성 항염증약
• 기타

제5장 암 지지 치료제 시장 : 용도별

• 개요
• 유방암
• 폐암
• 대장암
• 전립선암
• 간암
• 위암
• 기타

제6장 암 지지 치료제 시장 : 유통 채널별

• 개요
• 병원 약국
• 드러그스토어 및 소매 약국
• 온라인 프로바이더

제7장 암 지지 치료제 시장 : 지역별

• 개요
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 독일
  • 프랑스
  • 영국
  • 이탈리아
  • 스페인
  • 기타
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 호주
  • 한국
  • 기타
• 라틴아메리카·중동 및 아프리카
  • 브라질
  • 사우디아라비아
  • 남아프리카공화국
  • 기타

제8장 경쟁 상황

• 서론
• 주요 성공 전략
• 주요 10사의 제품 매핑
• 경쟁 대시보드
• 경쟁 히트맵
• 주요 기업의 포지셔닝, 2022년

제9장 기업 개요

• Novartis AG
• Johnson & Johnson
• Amgen Inc.
• Baxter International Inc.
• F. Hoffmann-La Roche AG
• Helsinn Healthcare SA
• Heron Therapeutics, Inc.
• Merck & Co., Inc.
• Teva Pharmaceutical Industries Ltd.
• Pfizer Inc.

KSA

영문 목차

영문목차

The main factors that drive the cancer supportive care drugs include rise in prevalence of cancer and adverse effects associated with the use of cancer drugs such as chemotherapy-induced anemia, nausea and vomiting. For instance, in February 2022, the World Health Organization (WHO) estimated that approximately 400,000 children develop cancer every year across the globe. In addition, a study conducted by the National Center for Biotechnology Information (NCBI) in April 2022 estimated that the occurrence rate of anemia was about 41.1% in patients suffering from breast cancer. Therefore, the rise in prevalence of cancer drives the growth of the market.

In addition, older people are more likely to develop cancer, which further fuels the demand for cancer support care drugs to treat various side effects. For instance, in October 2022, the World Health Organization (WHO) estimated that the global population aged 60 years and over is expected to double by 2050 to reach 2.1 billion. Moreover, according to the National Center for Biotechnology Information (NCBI), older adults are expected to experience anemia as a result of cancer treatment. Furthermore, increase in awareness among patients and healthcare professionals about the side effects cause by cancer treatments has led to an increase in preference for cancer support care drugs.

Moreover, growing awareness among both patients and healthcare professionals about the side effects induced by cancer treatments has driven a preference for cancer supportive care drugs. In addition, the growth in focus on enhancing patients' quality of life during cancer therapy drives the demand for effective solutions. As cancer prevalence continues to rise, particularly among specific demographics such as children and older adults, the demand for supportive care drugs is projected to witness sustained growth, underlining their pivotal role in comprehensive cancer care.

The cancer supportive care drugs market is segmented on the basis of type, application, distribution channel, and region to provide a detailed assessment of the market. By type, it is segmented into erythropoiesis-stimulating agents (ESA), granulocyte colony-stimulating factors (G-CSFs), antiemetics, bisphosphonates, opioids, NSAIDs (non-steroidal anti-inflammatory drugs), and others. On the basis of application, the market is categorized into breast cancer, lung cancer, colorectal cancer, prostate cancer, liver cancer, stomach cancer and others. Depending on distribution channel, the market is fragmented into hospital pharmacies, drug stores & retail pharmacies, and online providers. Region-wise, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).

The major key players that operate in the global cancer supportive care drugs market are Novartis AG, Johnson & Johnson, Amgen Inc., Baxter International Inc., F. Hoffmann-La Roche AG, Helsinn Healthcare SA, Heron Therapeutics, Inc., Merck & Co., Inc., Teva Pharmaceutical Industries Ltd. and Pfizer Inc. The key players have adopted strategies such as agreement and product approval to expand their product portfolio.

Key Benefits For Stakeholders

• This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the cancer supportive care drugs market analysis from 2022 to 2032 to identify the prevailing cancer supportive care drugs market opportunities.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the cancer supportive care drugs market segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global market.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
• The report includes the analysis of the regional as well as global cancer supportive care drugs market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

• Quarterly Update and* (only available with a corporate license, on listed price)
• 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
• Free Upcoming Version on the Purchase of Five and Enterprise User License.
• 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
• 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
• Free data Pack on the Five and Enterprise User License. (Excel version of the report)
• Free Updated report if the report is 6-12 months old or older.
• 24-hour priority response*
• Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

• Patient/epidemiology data at country, region, global level
• Regulatory Guidelines
• Additional company profiles with specific to client's interest
• Additional country or region analysis- market size and forecast
• Expanded list for Company Profiles
• Historic market data
• SWOT Analysis

Key Market Segments

By Type

• Erythropoiesis Stimulating Agents
• Granulocyte Colony Stimulating Factors
• Antiemetics
• Bisphosphonates
• Opioids
• Nonsteroidal Anti Inflammatory Drugs
• Others

By Application

• Breast Cancer
• Lung Cancer
• Colorectal Cancer
• Prostate Cancer
• Liver Cancer
• Stomach Cancer
• Others

By Distribution Channel

• Hospital Pharmacies
• Drug Stores and Retail Pharmacies
• Online Providers

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
• Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia-Pacific
• LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA

Key Market Players:

• Novartis AG
• Amgen Inc.
• Heron Therapeutics, Inc.
• Merck & Co., Inc.
• Helsinn Healthcare SA
• Pfizer Inc.
• Baxter International Inc.
• Johnson & Johnson
• F. Hoffmann-La Roche AG
• Teva Pharmaceutical Industries Ltd.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

• 1.1. Report description
• 1.2. Key market segments
• 1.3. Key benefits to the stakeholders
• 1.4. Research methodology
  • 1.4.1. Primary research
  • 1.4.2. Secondary research
  • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

• 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

• 3.1. Market definition and scope
• 3.2. Key findings
  • 3.2.1. Top impacting factors
  • 3.2.2. Top investment pockets
• 3.3. Porter's five forces analysis
  • 3.3.1. High bargaining power of suppliers
  • 3.3.2. Moderate threat of new entrants
  • 3.3.3. Moderate threat of substitutes
  • 3.3.4. Moderate intensity of rivalry
  • 3.3.5. High bargaining power of buyers
• 3.4. Market dynamics
  • 3.4.1. Drivers
    • 3.4.1.1. Growth in geriatric population
    • 3.4.1.2. Rise in prevalence of cancer and adverse effects associated with use of cancer drugs.
    • 3.4.1.3. Increase in adoption of cancer supportive care drugs.
  • 3.4.2. Restraints
    • 3.4.2.1. Advancements in targeted therapy for cancer
  • 3.4.3. Opportunities
    • 3.4.3.1. Increase in R&D and number of pipeline cancer supportive care drugs

CHAPTER 4: CANCER SUPPORTIVE CARE DRUGS MARKET, BY TYPE

• 4.1. Overview
  • 4.1.1. Market size and forecast
• 4.2. Erythropoiesis Stimulating Agents
  • 4.2.1. Key market trends, growth factors and opportunities
  • 4.2.2. Market size and forecast, by region
  • 4.2.3. Market share analysis by country
• 4.3. Granulocyte Colony Stimulating Factors
  • 4.3.1. Key market trends, growth factors and opportunities
  • 4.3.2. Market size and forecast, by region
  • 4.3.3. Market share analysis by country
• 4.4. Antiemetics
  • 4.4.1. Key market trends, growth factors and opportunities
  • 4.4.2. Market size and forecast, by region
  • 4.4.3. Market share analysis by country
• 4.5. Bisphosphonates
  • 4.5.1. Key market trends, growth factors and opportunities
  • 4.5.2. Market size and forecast, by region
  • 4.5.3. Market share analysis by country
• 4.6. Opioids
  • 4.6.1. Key market trends, growth factors and opportunities
  • 4.6.2. Market size and forecast, by region
  • 4.6.3. Market share analysis by country
• 4.7. Nonsteroidal Anti Inflammatory Drugs
  • 4.7.1. Key market trends, growth factors and opportunities
  • 4.7.2. Market size and forecast, by region
  • 4.7.3. Market share analysis by country
• 4.8. Others
  • 4.8.1. Key market trends, growth factors and opportunities
  • 4.8.2. Market size and forecast, by region
  • 4.8.3. Market share analysis by country

CHAPTER 5: CANCER SUPPORTIVE CARE DRUGS MARKET, BY APPLICATION

• 5.1. Overview
  • 5.1.1. Market size and forecast
• 5.2. Breast Cancer
  • 5.2.1. Key market trends, growth factors and opportunities
  • 5.2.2. Market size and forecast, by region
  • 5.2.3. Market share analysis by country
• 5.3. Lung Cancer
  • 5.3.1. Key market trends, growth factors and opportunities
  • 5.3.2. Market size and forecast, by region
  • 5.3.3. Market share analysis by country
• 5.4. Colorectal Cancer
  • 5.4.1. Key market trends, growth factors and opportunities
  • 5.4.2. Market size and forecast, by region
  • 5.4.3. Market share analysis by country
• 5.5. Prostate Cancer
  • 5.5.1. Key market trends, growth factors and opportunities
  • 5.5.2. Market size and forecast, by region
  • 5.5.3. Market share analysis by country
• 5.6. Liver Cancer
  • 5.6.1. Key market trends, growth factors and opportunities
  • 5.6.2. Market size and forecast, by region
  • 5.6.3. Market share analysis by country
• 5.7. Stomach Cancer
  • 5.7.1. Key market trends, growth factors and opportunities
  • 5.7.2. Market size and forecast, by region
  • 5.7.3. Market share analysis by country
• 5.8. Others
  • 5.8.1. Key market trends, growth factors and opportunities
  • 5.8.2. Market size and forecast, by region
  • 5.8.3. Market share analysis by country

CHAPTER 6: CANCER SUPPORTIVE CARE DRUGS MARKET, BY DISTRIBUTION CHANNEL

• 6.1. Overview
  • 6.1.1. Market size and forecast
• 6.2. Hospital Pharmacies
  • 6.2.1. Key market trends, growth factors and opportunities
  • 6.2.2. Market size and forecast, by region
  • 6.2.3. Market share analysis by country
• 6.3. Drug Stores and Retail Pharmacies
  • 6.3.1. Key market trends, growth factors and opportunities
  • 6.3.2. Market size and forecast, by region
  • 6.3.3. Market share analysis by country
• 6.4. Online Providers
  • 6.4.1. Key market trends, growth factors and opportunities
  • 6.4.2. Market size and forecast, by region
  • 6.4.3. Market share analysis by country

CHAPTER 7: CANCER SUPPORTIVE CARE DRUGS MARKET, BY REGION

• 7.1. Overview
  • 7.1.1. Market size and forecast By Region
• 7.2. North America
  • 7.2.1. Key market trends, growth factors and opportunities
  • 7.2.2. Market size and forecast, by Type
  • 7.2.3. Market size and forecast, by Application
  • 7.2.4. Market size and forecast, by Distribution Channel
  • 7.2.5. Market size and forecast, by country
    • 7.2.5.1. U.S.
    • 7.2.5.1.1. Market size and forecast, by Type
    • 7.2.5.1.2. Market size and forecast, by Application
    • 7.2.5.1.3. Market size and forecast, by Distribution Channel
    • 7.2.5.2. Canada
    • 7.2.5.2.1. Market size and forecast, by Type
    • 7.2.5.2.2. Market size and forecast, by Application
    • 7.2.5.2.3. Market size and forecast, by Distribution Channel
    • 7.2.5.3. Mexico
    • 7.2.5.3.1. Market size and forecast, by Type
    • 7.2.5.3.2. Market size and forecast, by Application
    • 7.2.5.3.3. Market size and forecast, by Distribution Channel
• 7.3. Europe
  • 7.3.1. Key market trends, growth factors and opportunities
  • 7.3.2. Market size and forecast, by Type
  • 7.3.3. Market size and forecast, by Application
  • 7.3.4. Market size and forecast, by Distribution Channel
  • 7.3.5. Market size and forecast, by country
    • 7.3.5.1. Germany
    • 7.3.5.1.1. Market size and forecast, by Type
    • 7.3.5.1.2. Market size and forecast, by Application
    • 7.3.5.1.3. Market size and forecast, by Distribution Channel
    • 7.3.5.2. France
    • 7.3.5.2.1. Market size and forecast, by Type
    • 7.3.5.2.2. Market size and forecast, by Application
    • 7.3.5.2.3. Market size and forecast, by Distribution Channel
    • 7.3.5.3. UK
    • 7.3.5.3.1. Market size and forecast, by Type
    • 7.3.5.3.2. Market size and forecast, by Application
    • 7.3.5.3.3. Market size and forecast, by Distribution Channel
    • 7.3.5.4. Italy
    • 7.3.5.4.1. Market size and forecast, by Type
    • 7.3.5.4.2. Market size and forecast, by Application
    • 7.3.5.4.3. Market size and forecast, by Distribution Channel
    • 7.3.5.5. Spain
    • 7.3.5.5.1. Market size and forecast, by Type
    • 7.3.5.5.2. Market size and forecast, by Application
    • 7.3.5.5.3. Market size and forecast, by Distribution Channel
    • 7.3.5.6. Rest of Europe
    • 7.3.5.6.1. Market size and forecast, by Type
    • 7.3.5.6.2. Market size and forecast, by Application
    • 7.3.5.6.3. Market size and forecast, by Distribution Channel
• 7.4. Asia-Pacific
  • 7.4.1. Key market trends, growth factors and opportunities
  • 7.4.2. Market size and forecast, by Type
  • 7.4.3. Market size and forecast, by Application
  • 7.4.4. Market size and forecast, by Distribution Channel
  • 7.4.5. Market size and forecast, by country
    • 7.4.5.1. Japan
    • 7.4.5.1.1. Market size and forecast, by Type
    • 7.4.5.1.2. Market size and forecast, by Application
    • 7.4.5.1.3. Market size and forecast, by Distribution Channel
    • 7.4.5.2. China
    • 7.4.5.2.1. Market size and forecast, by Type
    • 7.4.5.2.2. Market size and forecast, by Application
    • 7.4.5.2.3. Market size and forecast, by Distribution Channel
    • 7.4.5.3. India
    • 7.4.5.3.1. Market size and forecast, by Type
    • 7.4.5.3.2. Market size and forecast, by Application
    • 7.4.5.3.3. Market size and forecast, by Distribution Channel
    • 7.4.5.4. Australia
    • 7.4.5.4.1. Market size and forecast, by Type
    • 7.4.5.4.2. Market size and forecast, by Application
    • 7.4.5.4.3. Market size and forecast, by Distribution Channel
    • 7.4.5.5. South Korea
    • 7.4.5.5.1. Market size and forecast, by Type
    • 7.4.5.5.2. Market size and forecast, by Application
    • 7.4.5.5.3. Market size and forecast, by Distribution Channel
    • 7.4.5.6. Rest of Asia-Pacific
    • 7.4.5.6.1. Market size and forecast, by Type
    • 7.4.5.6.2. Market size and forecast, by Application
    • 7.4.5.6.3. Market size and forecast, by Distribution Channel
• 7.5. LAMEA
  • 7.5.1. Key market trends, growth factors and opportunities
  • 7.5.2. Market size and forecast, by Type
  • 7.5.3. Market size and forecast, by Application
  • 7.5.4. Market size and forecast, by Distribution Channel
  • 7.5.5. Market size and forecast, by country
    • 7.5.5.1. Brazil
    • 7.5.5.1.1. Market size and forecast, by Type
    • 7.5.5.1.2. Market size and forecast, by Application
    • 7.5.5.1.3. Market size and forecast, by Distribution Channel
    • 7.5.5.2. Saudi Arabia
    • 7.5.5.2.1. Market size and forecast, by Type
    • 7.5.5.2.2. Market size and forecast, by Application
    • 7.5.5.2.3. Market size and forecast, by Distribution Channel
    • 7.5.5.3. South Africa
    • 7.5.5.3.1. Market size and forecast, by Type
    • 7.5.5.3.2. Market size and forecast, by Application
    • 7.5.5.3.3. Market size and forecast, by Distribution Channel
    • 7.5.5.4. Rest of LAMEA
    • 7.5.5.4.1. Market size and forecast, by Type
    • 7.5.5.4.2. Market size and forecast, by Application
    • 7.5.5.4.3. Market size and forecast, by Distribution Channel

CHAPTER 8: COMPETITIVE LANDSCAPE

• 8.1. Introduction
• 8.2. Top winning strategies
• 8.3. Product mapping of top 10 player
• 8.4. Competitive dashboard
• 8.5. Competitive heatmap
• 8.6. Top player positioning, 2022

CHAPTER 9: COMPANY PROFILES

• 9.1. Novartis AG
  • 9.1.1. Company overview
  • 9.1.2. Key executives
  • 9.1.3. Company snapshot
  • 9.1.4. Operating business segments
  • 9.1.5. Product portfolio
  • 9.1.6. Business performance
• 9.2. Johnson & Johnson
  • 9.2.1. Company overview
  • 9.2.2. Key executives
  • 9.2.3. Company snapshot
  • 9.2.4. Operating business segments
  • 9.2.5. Product portfolio
  • 9.2.6. Business performance
• 9.3. Amgen Inc.
  • 9.3.1. Company overview
  • 9.3.2. Key executives
  • 9.3.3. Company snapshot
  • 9.3.4. Operating business segments
  • 9.3.5. Product portfolio
  • 9.3.6. Business performance
  • 9.3.7. Key strategic moves and developments
• 9.4. Baxter International Inc.
  • 9.4.1. Company overview
  • 9.4.2. Key executives
  • 9.4.3. Company snapshot
  • 9.4.4. Operating business segments
  • 9.4.5. Product portfolio
  • 9.4.6. Business performance
• 9.5. F. Hoffmann-La Roche AG
  • 9.5.1. Company overview
  • 9.5.2. Key executives
  • 9.5.3. Company snapshot
  • 9.5.4. Operating business segments
  • 9.5.5. Product portfolio
  • 9.5.6. Business performance
• 9.6. Helsinn Healthcare SA
  • 9.6.1. Company overview
  • 9.6.2. Key executives
  • 9.6.3. Company snapshot
  • 9.6.4. Operating business segments
  • 9.6.5. Product portfolio
  • 9.6.6. Key strategic moves and developments
• 9.7. Heron Therapeutics, Inc.
  • 9.7.1. Company overview
  • 9.7.2. Key executives
  • 9.7.3. Company snapshot
  • 9.7.4. Operating business segments
  • 9.7.5. Product portfolio
  • 9.7.6. Business performance
• 9.8. Merck & Co., Inc.
  • 9.8.1. Company overview
  • 9.8.2. Key executives
  • 9.8.3. Company snapshot
  • 9.8.4. Operating business segments
  • 9.8.5. Product portfolio
  • 9.8.6. Business performance
• 9.9. Teva Pharmaceutical Industries Ltd.
  • 9.9.1. Company overview
  • 9.9.2. Key executives
  • 9.9.3. Company snapshot
  • 9.9.4. Operating business segments
  • 9.9.5. Product portfolio
  • 9.9.6. Business performance
• 9.10. Pfizer Inc.
  • 9.10.1. Company overview
  • 9.10.2. Key executives
  • 9.10.3. Company snapshot
  • 9.10.4. Operating business segments
  • 9.10.5. Product portfolio
  • 9.10.6. Business performance
  • 9.10.7. Key strategic moves and developments

관련자료